Apogee Therapeutics, Inc. (APGE)
135.06
-0.02
(-0.01%)
USD |
NASDAQ |
Sep 01, 16:00
135.02
-0.04
(-0.03%)
After-Hours: 17:02
Apogee Therapeutics Research and Development Expense (Annual) : 214.42M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 214.42M |
| December 31, 2024 | 167.86M |
| Date | Value |
|---|---|
| December 31, 2023 | 68.42M |
| December 31, 2022 | 27.79M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Cogent Biosciences, Inc. | 265.16M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Intellia Therapeutics, Inc. | 379.09M |
| Revolution Medicines, Inc. | 978.68M |
| Erasca, Inc. | 92.85M |